Media headlines about BIOLASE (NASDAQ:BIOL) have trended somewhat positive on Sunday, Accern Sentiment Analysis reports. Accern scores the sentiment of media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. BIOLASE earned a coverage optimism score of 0.09 on Accern’s scale. Accern also gave headlines about the medical technology company an impact score of 44.578595410922 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Separately, ValuEngine raised shares of BIOLASE from a “sell” rating to a “hold” rating in a research note on Monday, October 2nd.
BIOLASE (BIOL) opened at $0.50 on Friday. BIOLASE has a 52 week low of $0.28 and a 52 week high of $1.87. The company has a market cap of $40.28, a price-to-earnings ratio of -1.61 and a beta of 2.32.
TRADEMARK VIOLATION WARNING: This news story was first posted by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this news story on another site, it was copied illegally and reposted in violation of international copyright & trademark law. The correct version of this news story can be read at https://stocknewstimes.com/2018/01/14/biolase-biol-given-coverage-optimism-rating-of-0-09.html.
BIOLASE Company Profile
BIOLASE, Inc (BIOLASE) is a medical device company that develops, manufactures, markets and sells laser systems in dentistry and medicine. The Company markets, sells, and distributes dental imaging equipment, including cone beam digital x-rays and computer-aided design (CAD)/computer-aided manufacturing (CAM) intra-oral scanners, in-office, chair-side milling machines and three-dimensional (3-D) printers.
Receive News & Ratings for BIOLASE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLASE and related companies with MarketBeat.com's FREE daily email newsletter.